Aytu Biopharma (AYTU) Cash from Investing Activities Growth (3y) (2018 - 2025)
Powered by 
Analysis
Aytu Biopharma (AYTU) Cash from Investing Activities Growth (3y) (2018 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 33.61% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -50.37% |
| Jun 30, 2025 | -319.05% |
| Mar 31, 2025 | 0.48% |
| Dec 31, 2024 | 26.98% |
| Sep 30, 2024 | 85.96% |
| Jun 30, 2024 | 75.89% |
| Dec 31, 2023 | -79.67% |
| Sep 30, 2023 | -103.64% |
| Jun 30, 2023 | -50.72% |
| Mar 31, 2023 | -85.73% |
| Dec 31, 2022 | 89.94% |
| Sep 30, 2022 | 26.83% |
| Jun 30, 2022 | 24.72% |
| Mar 31, 2022 | 12.80% |
| Dec 31, 2021 | -76.27% |
| Sep 30, 2021 | 34.29% |
| Jun 30, 2021 | -82.03% |
| Jun 30, 2020 | -27.73% |
| Mar 31, 2020 | 31.40% |
| Dec 31, 2019 | -28.97% |